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Abstract 
Somatic symptoms are commonly seen in patients with major depressive 
disorder (MDD) and might be associated with inflammatory activation. Cytosolic 
phospholipase A2 (cPLA2) and cyclo-oxygenase-2 (COX-2) are the key enzymes in 
the metabolism of polyunsaturated fatty acids (PUFAs), which in turn may play an 
important role in inflammation and somatic symptoms in depression. This study 
investigated the effects of BanI polymorphism of cPLA2 gene and COX-2 rs4648308 
genotypes on somatic symptoms and inflammatory marker in patients with MDD. 
Eighty-two patients with MDD were assessed for their psychopathology including 
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psychiatric and somatic symptoms, BanI polymorphism of cPLA2 and COX-2 
rs4648308 genotypes and CRP levels. The results revealed that MDD patients with 
the cPLA2 BanI GG genotypes had higher somatic symptoms and higher levels of 
C-reactive protein (CRP), while no differences were found among the COX-2 
rs4648308 genotypes. Inflammatory process, such as arachidonic acid cascade 
pathway, might help explain the effect of cPLA2 BanI polymorphism on the somatic 
symptoms, and may be a potential target for future investigation on treatment for 
MDD with somatic symptoms. However, the interpretation of the findings in this 
study is limited since we analyzed the data from a subset data from a larger study. 
 
Keywords: BanI polymorphism, Cytosolic phospholipase A2 gene, cPLA2, Major 
depressive disorder, MDD, HDRS 
 
1. INTRODUCTION 
Depressive disorders with predominantly somatic presentation are the most 
common form of depression. In a clinical study, somatic symptoms including 
sweating, headache, urinary freuqncy, indigestion and fatigue, were documented in up 
to 80% of a sample of major depression [1]. About two thirds of depressed patients 
complained of general aches and pains, implying the close relationship between 
somatic symptoms and depression [2]. On the other hand, somatic symptoms have 
been negatively associated with eicosapentanoic acid (EPA), a type of omega-3 (or 
n-3) polyunsaturated fatty acids (PUFAs) with anti-inflammatory actions [3, 4], and 
positively associated with arachidonic acid (AA), a type of omega-6 (or n-6) PUFAs 
which give deriatives to pro-inflammatory cytokines [4].  
Epidemiological studies [5, 6], case-control studies [7-12] , and clinical trials 
 3 
[13-18] all suggest that n-3 PUFAs might play an important role in major depressive 
disorder (MDD). Moreover, genotypes of the key enzymes for phospholipids 
metabolism, such as Phospholipase A2 (PLA2) and cyclo-oxygenase-2 (COX-2), have 
been associated with major depressive disorder [19, 20] and Interferon (IFN)-α
induced depression [21]. The major subtype of PLA2 enzymes is the cytosolic A2 
(cPLA2), and the gene for cPLA2 (PLA2G4A) has also been cloned and localized to 
chromosome 1q25 [22, 23]. Cytosolic calcium activates cPLA2, which in turn 
catalyzes the release of arachidonic acid (AA) from membrane phopshpolids. The 
gene coding for COX-2 (also known as prostaglandin-endoperoxidase synthase 2, 
hence the gene is termed PTGS2), converts AA to prostaglandins (PGs), is 
immediately centromeric of the cPLA2 locus. These two gene loci may share a 
common regulatory region since they are arranged in a head-to-head configuration. 
Six single nucleotide polymorphisms (SNPs) present in the PTGS2/cPLA2 and a 
SNP4 (located in the 5’-flanking region known as rs10798059 or so-called BanI SNP) 
were associated with schizophrenia [24-27]. Moreover, MDD [19] and IFN-αinduced 
depression associated somatic symptoms [21] have been associated with GG genotype 
of BanI polymorphism of the cPLA2 gene, while development of major depression 
has been associated with COX-2 rs4648308 AG genotype [21].  
The findings of genetic linkage studies in depression are promising in that they 
are able to provide more understanding of the disorder. However, even from the 
studies with large sample sizes and well-designed manner, the findings are not 
definitive because the effect sizes of the susceptibility loci are only modest [28]. 
MDD is a heterogeneous complex disease and clearly contributed to by multiple 
genes; therefore each of the genes to be detected might only have an effect size close 
to the lower limit. One of the possible alternative approaches is to study the 
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relationship between genetic variations and symptoms with similar mechanism rather 
than the disorder as a whole. Since somatic symptoms are common in MDD [29], and 
these symptoms are similar to PG- mediated sickness behavior [30]. Taken together, 
the AA cascade, via the actions of PGs and other inflammatory cytokines, may be 
important not only in the pathogenesis of depressive disorders but also in the 
manifestation of somatic symptoms. In addition, depression has also been associated 
with increased levels of pro-inflammatory markers, such as C- reactive protein (CRP) 
[31], and MDD associated somatic symptoms have also been associated with 
inflammation [4] and higher levels of proinflammatory cytokines [32]. The aim of the 
study is to investigate the effect of BanI polymorphism of cPLA2 gene and COX-2 
rs4648308 polymorphism on somatic symptoms in MDD with a subset data from a 
larger study [21]. We hypothesized patients with Ban I GG genotype will have more 
somatic symptoms than those with BanI AA or AG genotypes. 
2. PATIENTS AND METHODS 
2.1 Subjects 
Eligible patients, age between 18 to 60 years, were screened with the structured 
Mini-International Neuropsychiatric Interview (MINI) [33] by a senior psychiatric 
research nurse and interviewed by certified psychiatrists. The patients were recruited 
from the outpatient clinic of Department of Psychiatry. Patients with a DSM-IV [34] 
diagnosis of MDD with a current major depressive epsiosde and a score of 17 or 
higher on the 21-item Hamilton Rating Scale for Depression (HDRS) [35] were 
enrolled in the study. All subjects were native Taiwanese and were biologically 
unrelated. Other minorities were excluded from this study. All patients were free of 
any medical illness on the comprehensive evaluations from medical history, physical 
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examination and laboratory tests. Those who had a recent or past history of other 
major psychiatric disorders were exclued. The patients were also free from any 
medication for at least 4 weeks prior to the study. Patients had to fully understand and 
sign the informed consent before enrolment. The patients were also sampled for 
venous blood for genotyping. The study was approved by the China Medical 
University Hospital Institutional Review Board. 
2.2 Assessments 
2.2.1 Mini-International Neuropsychiatric Interview (MINI) 
MINI is a short structured clinical interview which enables researchers to make 
diagnoses of psychiatric disorders according to DSM-IV or ICD-10 [33]. The 
administration time of the interview is approximately 15 minutes and was designed 
for epidemiological studies and multicenter clinical trials.The information of 
translation, validation and instruction of Taiwanese version of MINI can be accessed 
on the website of Taiwanese Society of Psychiatry 
(http://www.sop.org.tw/dow_a.htm). 
2.2.2 The Hamilton Depression Rating Scale - 21 Item (HDRS) 
The Semi-structured version of the 21-item HDRS was used to assess the 
severity and the different clusters of depressive symptoms [35]. The HDRS items 
were divided into the following published clusters [36]: Core (items 1,2,7,8,10,13), 
Sleep (items 4,5,6), Activity (items 7,8), Anxiety (items 9,10,11,12,13), Psychic 
Anixety (items 9,10), Somatic (items, 11,12,13), and Delusion (items 2,15,20). The 
inter-rater reliability of HDRS has been described elsewhere [11]. 
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2.3 Laboratory Assessment 
Genomic DNA was extracted from peripheral blood using DNA extraction kits 
(Qiagen, Hilden, Germany). The genotyping of cPLA2 BanI and COX-2 rs4648308 
polymorphisms were performed by PCR-based restriction fragment length 
polymorphism (RFLP) analysis with forward and reverse primers (cPLA2 BanI: 
forward, 5’-TGTGCATTTGCTCAAAGGAG-3’, and reverse, 
5’-ATCTTGGCTCACTGCAACCT-3’; COX-2 rs4648308: forward, 
5’-CGACACTGTGTTGGAAAATGTCT-3’, and reverse, 5’- 
AATTTCCTCCTCTTTGAACTTCTTAACTTTGGGCC-3’) to generate a PCR 
product of 342 and 171 base pairs (bp), respectively. The reaction volume was 25μl in 
each 0.2ml PCR tube, with reaction component concentrations of 200μM for each 
dNTP, 2mM MgSO4, 20mM Tris-HCl (pH 8.8), 10mM KCl, 0.1% gelatin, 0.4μM of 
each primer, and 2.5U Taq DNA polymerase (BioLabs, Beverly, MA, USA), and 
50-100ng of genomic DNA. PCR was performed with an initial denaturation 
temperature of 94°C for 3 minutes, followed by 40 cycles of 95°C for 45 seconds, 
60°C for 1 minute, and 72°C for 1 minute, and a final elongation at 72°C for 10 
minutes. The PCR products were completely digested with 5 units for each SNP 
(BioLabs, Beverly, MA, USA). Then we separated DNA fragments on 2% agarose 
gels followed by ethidium bromide staining. Positive and negative controls were 
implemented in all gels. 
The patients enrolled in the study were assessed for the level of inflammatory 
marker, CRP. CRP levels were measured by nephelometry, a latex particle-enhanced 
immunoassay (TBA-200FR, Tokyo, Japan), using a fully automatic biochemical 
analyzer (Unicel DxC 800 Synchron Clinical System; Beckman Coulter, Fullerton, 
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CA, USA) at the Clinical Laboratory Department of the China Medical University 
Hospital. The inter- and intra-assay coefficients of variations (CVs) were <2.0% and 
<1.9%, respectively. The lower detection limit of the assay was 0.01 mg/dL.  
2.4 Statistical Analysis 
All statistical analysis was carried out with the Statistical Package for the Social 
Science (SPSS), version 17.0 for windows.The Chi-square test was applied to 
examine Hardy-Weinberg equilibrium (HWE) and to assess whether the distribution 
of the allele frequencies differed in male and female MDD groups. The HWE is a 
principle stating an ideal condition that allele and genotype frequencies in a 
population will remain constant form generation to generation in absence of other 
evolutionary influences, e.g., mate choice, mutation, selection, genetic drift, gene flow 
and meiotic drive. The Mann-Whitney and the Kruskal-Wallis tests were applied as 
non-parametric tests when the data distribution was not Gaussian. The Kruskal-Wallis 
test was used to study the effect of the genotypes (AA, AG, and GG genotypes) of 
cPLA2 BanI polymorphism and COX-2 rs4648308 polymorphism on the 7 
symptomatologic clusters and the total score of HDRS. Multivariate linear regression 
was used to examine the associations between somatic symptoms and demographic 
variables, BanI and COX-2 rs4648308 genotypes, and CRP levels. The Bonferroni 
method was used to adjust p values in post hoc analysis owing to multiple 
comparisons. All p values were two-tailed and p< 0.01 was considered statistically 
significant.  
3. RESULTS 
Eighty-two patients were enrolled in the study, with 21 males and 61 females. 
The frequencies of alleles and genotypes of the cPLA2 BanI polymorphism in this 
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group were 70.7% for A, 29.3% for G, 51.2% for AA, 39.0% for AG, and 9.8% for 
GG. Genotype distributions in male, female, and all patients with MDD were all in 
the HWE for BanI polymorphism, while only the COX-2 rs4648308 polymorphism 
violated the HWE test. There were no differences in age and gender between the A 
allele carriers (AA and AG genotypes) and GG genotype for BanI polymorphism 
(Table 1) and among the COX-2 rs4648308 AA, AG and GG genotypes (Table 2, 
Supplementary Table S1). There were also no differences in mean HDRS cluster 
scores of the BanI polymorphism genotypes, except for Somatic clustser; BanI GG 
genotype had higher Somatic cluster score than BanI AA and AG genotypes 
(p=0.001). BanI GG genotype also had higher CRP level than the other 2 genotypes 
(p=0.004) (Table 1). On the other hand, there were no differences in mean HDRS 
cluster scores and CRP level among the COX-2 rs4648308 genotypes (Table 2). 
Moreover, no significant correlation was found between HDRS symptom clusters and 
CRP (Data not shown). Meanwhile, regression analysis showed BanI polymorphism 
is the main predictor of somatic sympotms in MDD ( p<0.001, Table 3).  
The SNP gender interaction for BanI polymorphism was significant for the 
HDRS somatic cluster (p<0.003, Supplementary Table S2), where females with BanI 
GG genotype had higher Somatic cluster scores than the females with BanI AA or AG 
genotypes. On the other hand, there was no significance of COX-2 rs4648308- gender 
interaction on HDRS symptom clusters (Data not shown). 
4. DISCUSSION 
The major finding of this study is that MDD patients with BanI polymorphism of 
cPLA2 gene GG genotypes had more somatic symptoms than patients with BanI A 
allele carriers (AA or AG genotypes), which was concordant to our initial hypothesis. 
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The somatic symptoms included effects of autonomic overactivity, “butterflies,” 
indigestion, stomach cramps, belching, diarrhea, palpitations, hyperventilations, 
paresthesia, sweating, flushing, tremor, headache, urinary frequency, loss of appetite, 
heaviness in limbs, back or head, backaches, headache, muscle aches, loss of energy, 
and fatigability. Although the exact function of BanI polymorphism cPLA2 gene still 
requires further investigation, PLA2 are enzymes involved in phospholipids 
metabolism, cell membrane remodeling and intracellular signaling, while cPLA2 is 
responsible for release of AA and EPA from cell membrane. Moreover, BanI 
polymophism has been associated with increased cPLA2 activity in both patients with 
psychiatric disorders including MDD [19] and schizophrenia [26], which further 
implies MDD may be associated with disordered metabolism of phospholipids and 
inflammatory process. In addition, cPLA2 BanI polymorphism may be associated 
with somatic symptoms in MDD via the changes in EPA levels. PLA2 enzyme 
deacylates EPA from membrane phospholipids, thus an increased PLA2 enzyme 
activity in BanI GG genotypes may lead to depletion changes in EPA levels [21], 
which contributes to perception of somatic complaints in MDD [4]. On the other hand, 
although polymorphism of COX-2 rs4648308 genotypes have been associated with 
development of MDD, no association was found between COX-2 rs4648308 
polymorphism and somtiac symptoms in MDD in this study. Moreover, although the 
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distribution of the COX-2 rs4648308 in the study sample violated HWE, some 
authors have argued that this is acceptable, since “cases” in study samples cannot be 
considered “general population” [37]. 
Somatic symptoms are common in depression; while prostaglandin 
administration associated sickness behavior including malaise, fatigue, and loss of 
appetite are similar to somatic symptoms in depression [30, 38]. The endogenous 
metabolism of PGs are modulated by PUFAs [39], and cPLA2 is the key enzyme to 
catalyze the release of AA, the precursor of PGE2, from membrane phospholipids 
[40]. AA is then converted to PGE2 by COX-2. The AA-derived PGs and other 
pro-inflammatory cytokines may then enhance painful sensations and hypersensitivity 
of sickeness repsonse on the neurons, glia and endothelial cells [41], which may be 
presented as somatic presentations in patients with depression. Moreover, blood AA 
level has also been positively associated with somatic symptoms in a clinical study 
[4].  
The second major finding of this study is that MDD patients with BanI 
polymorphism of cPLA2 gene GG genotypes had higher CRP levels than patients 
with BanI A allele carriers (AA or AG genotypes). Depression has been associated 
with higher levels of CRP [31], while a clinical study showed that CRP significantly 
decreased in patients with MDD after receiving anti-depressant treatments [42]. 
Moreover, Rapaport et al had reported that ‘high’ inflammation group, including 
higher levels of CRP, of patients with MDD responded better to EPA treatment when 
compared to the ‘low’ inflammation group in MDD [43]. Hence, BanI GG genotype 
with an elevated CRP level in MDD may be an indicator for better response to EPA 
treatment. 
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We speculate that n-3 PUFAs are able to improve somatic symptoms, since 
docosahexaenoic acid (DHA) and EPA may lead to reduced eicosanoids and cytokines 
production of the neurons [44] by antagonizing the actions of AA, reducing PGE2 
synthesis, inactivating IL-1 induced neurotransmitter release of nucleus accumbens 
[44]. In addition, changes in the n-3 to n-6 PUFAs ratio may affect monoamine 
neurotransmission [45], and possibly increase the risk of developing depression [46] 
and somatic symptoms. Thus, the balance between the n-3 PUFAs and n-6 PUFAs 
may be crucial in manifestation of somatic symptoms in depression. 
The present study also showed the effect of BanI genotype on somatic symptoms 
is more prominent in females than in males. This may imply that cPLA2 gene has 
different effect on gender in MDD. In clinical practice, female patients with MDD 
seem to have more unexplained somatic symptoms than in male patietns with MDD 
[47]; however, there is no appropriate biological explanation for the difference. The 
findings in the present study may provide a possible explanation for the gender 
difference in the prevalence of somatic symptoms in MDD. It is important to note that 
the cPLA2 BanI polymorphism only accounted for only 20% (R2) of the variation of 
somatic symptoms in the whole group, and 24% (R2) of the variation of somatic 
symptoms in the female patients with MDD. Therefore, other variations for somatic 
symptoms in MDD are still to be explained by the effects of other genes. Furthermore, 
the interaction between this susceptibility gene and the environment factors, such as 
perinatal insults, deprivation of parental care since young age, exposure to conflicts 
and violence, substance use, head injury, and stressful life events, should not be 
underestimated [48].  
One of the limitation of the this study was that we did not include healthy 
controls in this study for comparison. Hence, we were not able to examine the effect 
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of cPLA2 BanI polymorphism with somatic symptoms in the healthy control group. 
Moreover, the interpretation of the findings in this study is limited because we 
analyzed the data from a subset data from a larger study with a small sample size . 
Hence, the small sample size may account for the lack of genotypic association of 
COX-2 rs4648308 in MDD patients, and limit generalization of this study findings. 
However, one of the strengths of this study is that the population in this study is of 
homogenous nature, where the differences of somatic symptoms and CRP levels of 
both groups are modest, despite statistical significance in the Ban I genotype analysis. 
In addition, our sample was also unequal in both sexes and the male sample was small 
(n=21). Thus, the lack of significance of BanI polymorphism on the male’s Somatic 
cluster needs to be interpreted with caution. The environmental factors were also not 
assessed to examine the interaction with the cPLA2 gene.  
5. CONCLUSIONS 
The present study provided that BanI polymorphism of cPLA2 gene, but not 
COX-2 rs4648308 polymorphism, may be associated with somatic symptoms in 
patients with MDD in the Taiwanese population, and this effect may perhaps be via 
inflammatory actions such as the AA cascade pathway. Since depression is 
heterogeneous in terms of etiology and symptomatologic presentation, our result 
implies that the effect of specific genotype might only be specific to certain 
symptomatologic cluster in the genetic association studies in depression. We propose 
that our findings should be replicated with a larger sample size, where future work is 
required to establish the assocation between BanI polymophism and somatic 
symptomsm in MDD, and whether BanI GG genotype with an elevated CRP is a 
predictor for better response to EPA treatment. 
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Summery 
Cytosolic phospholipase A2 (cPLA2) and cyclo-oxygenase-2 (COX-2) are the 
key enzymes in the metabolism of polyunsaturated fatty acids (PUFAs), which in turn 
may play an important role in inflammation and somatic symptoms in depression. 
This study investigated the effects of BanI polymorphism of cPLA2 gene and COX-2 
rs4648308 genotypes on somatic symptoms in patients with MDD. Eighty-two 
paitents with MDD were assessed for psychiatric and somatic symptoms, BanI 
polymorphism of cPLA2 and COX-2 rs4648308 genotypes and CRP levels. The 
results revealed that MDD patients with the cPLA2 BanI GG genotypes had higher 
somatic symptoms and higher levels of C-reactive protein (CRP), while no differences 
were found among the COX-2 rs4648308 genotypes. Inflammatory process, such as 
arachidonic acid cascade pathway, might help explain the effect of cPLA2 BanI 
polymorphism on the somatic symptoms, and may be a potential target for future 
investigation on treatment for MDD with somatic symptoms. However, the 
interpretation of the findings in this study is limited since we analyzed the data from a 
subset data from a larger study. 
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Table 1 Demographic Data and Hamilton Depression Rating Scale Scores and 
the cPLA2 BanI Polymorphism Genotypes (A allele and GG genotype) 











36.9(12.1) 35.3(8.3) .713  
Gender, Male 
N (%) 
19(26%) 2(25%) ----  
HDRS Total 27.3(5.4) 29.3(7.2) .344  
HDRS Core 15.1(2.4) 15.8(2.3) .472  
HDRS Sleep 3.5(1.7) 3.4(2.5) .847  
HDRS 
Activity 
3.8(1.4) 3.9(1.6) .822  
HDRS Psychic 
Anxiety 
4.5(1.6) 4.1(1.6) .525  
HDRS 
Somatic 
4.5(1.7) 5.8(.7) .001*  
HDRS 
Delusion 
3.8(1.7) 4.8(2.3) .173  
CRP 0.8(0.2) 0.9(0.2) .004*  
N=82 in this analysis 
Note: CRP, high-sensitivity C-reactive protein; HDRS, Hamilton Depression Rating 
Scale; N, number; SD, standard deviation; yrs, years. 
The Chi-square test was applied to examine Hardy-Weinberg equilibrium. T-test was 
applied to compare the HDRS cluster scores between the two groups. 
The Bonferroni method was used to adjust p values in post hoc analysis owing to 
multiple comparisons, * indicates statistical signifiance where p<0.01. 
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Table 2 Demographic Data and Hamilton Depression Rating Scale Scores and 
the COX-2 rs4648308 Genotypes  











42.6(13.7) 37.9(11.8) 35.7(11.4) 0.312 
HDRS Total 30.6(4.9) 28.9(6.6) 26.8(5.3) 0.129 
Gender, Male 
N(%) 
0(0%) 6(7.3%) 15(18.3%) 0.132 
HDRS “Core” 15.4(2.0) 16.1(2.6) 14.9(2.3) 0.239 
HDRS Sleep 4.6(1.3) 3.3(1.8) 3.4(1.7) 0.220 
HDRS 
Activity 
4.1(1.7) 4.1(1.6) 3.7(1.3) 0.452 
HDRS Psychic 
Anxiety 
4.0(2.4) 4.2(1.6) 4.6(01.5) 0.508 
HDRS 
Somatic 
4.3(2.4) 5.1(1.5) 4.6(1.6) 0.421 
HDRS 
Delusion 
5.0(1.4) 4.6(1.9) 3.6(1.8) 0.043 
CRP 0.9(0.2) 0.8(0.2) 0.8(0.2) 0.277 
N=82 in this analysis. 
Note: CRP, high-sensitivity C-reactive protein; HDRS, Hamilton Depression Rating 
Scale; N, number; SD, standard deviation; yrs, years. 
The Chi-square test was applied to examine Hardy-Weinberg equilibrium. 
T-test was applied to compare the HDRS scores in both groups. 
The Bonferroni method was used to adjust p values in post hoc analysis owing to 
multiple comparisons, statistical signifiance is indicated when p<0.01. 




Table 3 Predictors of Somatic Symptoms in MDD 
 Somatic   
 Beta T 
Gender .056 .531 
Age .036 .345 
Ban I Genotype 0.429 4.081*** 
COX-2 rs4648308 -.113 -1.088 
CRP -.057 -.548 
N= 82 in this analysis. 
Note: CRP, high-sensitivity c-reactive protein; MDD, major depressive disorder; Som, 
somatic symptoms. 
Linear regression is used to examine the preidctors of somatic symptoms. 
*** indicates statistical significance of p<0.001 
 
Highlights 
 We investigated the effects of BanI polymorphism of cPLA2 gene and COX-2 
rs4648308 genotypes on somatic symptoms and inflammatory marker in 
patients with MDD. 
 Patients with Major depressive disorder (MDD) with the cPLA2 BanI GG 
genotypes had higher somatic anxiety symptoms and higher levels of 
C-reactive protein (CRP). 
 Female patients with MDD with the cPLA2 BanI GG genotypes had higher 
somatic anxiety symptoms and higher levels of C-reactive protein (CRP). 
 Inflammatory process, such as arachidonic acid cascade pathway, might help 
explain the effect of cPLA2 BanI polymorphism on the somatic anxiety 
symptoms, and may be a potential target for future investigation on treatment 
for MDD with somatic symptoms. 
 
